Výsledky vyhledávání

Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity

Autor: Ashwin N. Ananthakrishnan, Lee M. Kaplan, Ricard Masia, Russell P. Goodman, Manish Gala, Kathleen E. Corey, N. Borren, Andrew Warren, Raymond T. Chung, Suraj J. Patel, Martin L. Yarmush, Alyssa C. Ehrlich, Sangeeta N. Bhatia, Erik DiGiacomo, Ida J Hatoum Moeller, Jay Luther

Publikováno v: Hepatology Communications

Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD). Connexin 32 (Cx32), the primary liver gap junction protein, is capable of modulating hepatic innate immune response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14939c12aac2258ce2ace1aadb4dbbff
https://doi.org/10.1002/hep4.1179

Zobrazit plný text záznamu

Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn’s Disease Is Not Associated with Emergence of Novel Inflammatory Pathways

Autor: Maneesh Dave, N. Borren, Manish Gala, Suraj J. Patel, Ashwin N. Ananthakrishnan, Ramnik J. Xavier, Jay Luther

Publikováno v: Digestive Diseases and Sciences. 63:738-745

BACKGROUND: While monoclonal antibodies against tumor necrosis factor-α (TNFα) are effective in treating Crohn’s disease (CD), approximately one-third of patients lose response. The mechanisms underlying this loss of response remain elusive. AIM:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273b164b2ef570d54dd1b9080bc4d4e7
https://doi.org/10.1007/s10620-018-4932-8

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

DOP30 Multi-‘omics profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse

Autor: Ruslan I. Sadreyev, Amit Joshi, Ashwin N. Ananthakrishnan, N. Borren, Hera Vlamakis, Gracia Bonilla, Damian R. Plichta, Ramnik J. Xavier

Publikováno v: Journal of Crohn's and Colitis. 14:S069-S070

Background Inflammatory bowel diseases (IBD) are characterised by intermittent relapses and their course is heterogeneous and often unpredictable. The ability of protein, metabolite, or microbial biomarkers to predict relapse in patients with quiesce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3240df062e3ce96715b15016161e6023
https://doi.org/10.1093/ecco-jcc/jjz203.069

Zobrazit plný text záznamu

P778 Longitudinal trajectory of fatigue in inflammatory bowel disease patients: a prospective study

Autor: N. Borren, J. van der Woude, Mph Millie D. Long Md, Ashwin N. Ananthakrishnan, Robert S. Sandler

Publikováno v: Journal of Crohn's and Colitis. 14:S616-S617

Background Fatigue is a commonly reported and sometimes disabling symptom in patients with inflammatory bowel disease (IBD). Its prevalence, mechanism, and impact remain poorly understood. Using a large cohort of patients with IBD, we aimed to prospe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b49922cddccb1cec5778e97857348813
https://doi.org/10.1093/ecco-jcc/jjz203.906

Zobrazit plný text záznamu

P490 Assessment of body weight changes in patients with inflammatory bowel diseases initiating biologic therapy: A prospective cohort study

Autor: Ashwin N. Ananthakrishnan, Alison T. Jess, John J. Garber, P H M Li, N. Borren, William Tan, Francis Colizzo, Jay Luther, Hamed Khalili

Publikováno v: Journal of Crohn's and Colitis. 14:S430-S430

Background Biologic therapies are effective in inducing sustained clinical and endoscopic remission in inflammatory bowel diseases. While side effects are infrequent, prior studies have inconsistently suggested that tumour necrosis factor α (anti-TN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50d472f507c95ed7cddbd18f23a2053d
https://doi.org/10.1093/ecco-jcc/jjz203.619

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání